Local delivery of recombinant osteoprotegerin enhances postorthodontic tooth stability. Hudson JB, Hatch N, Hayami T, et al. Calcif Tissue Int 90: 330-342, 2012. PMID: 22382900
Local delivery of osteoprotegerin inhibits mechanically mediated bone modelling in orthodontic tooth movement. Dunn MD, Park CH, Kostenuik PJ, Kapila S, and Giannobile WF. Bone 41: 446-455, 2007. PMID: 17588510
RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. Jin Q, Cirelli JA, Park CH, Kostenuik PJ, and Giannobile WF. J Periodontol 78: 1300-1308, 2007. PMID: 17608585
Inhibition of bone resorption by OPG or alendronate significantly reduced bone growth, molar eruption and tooth root development in neonatal rats. Kostenuik PJ, Ominsky MS, Roudier-Meyer M, Stolina M, Warmington K, Gristanti M, Asuncion F, Barrero M, Dwyer D, Li X, Niu QT, Simonet WS, Ke HZ. 5th International Conference on Children’s Bone Health, Cambridge UK, 2009 (Abstract).
OPG-Fc but not zoledronic acid discontinuation reverses radiographic and histologic indices of osteonecrosis of the jaws (ONJ) in a mouse model. De Molon R, Shimamoto H, Bezouglaia O, Pirih F, Dry S, Kostenuik P, Dwyer D, Boyce RW, Aghaloo , Tetradis S. J Bone Miner Res 29 (Suppl. 1):S156, 2014 (Abstract).
RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. Aghaloo TL, Cheong S, Bezouglaia O, Kostenuik P, Atti E, Dry SM, Pirih FQ, Tetradis S. J Bone Miner Res 29: 843-854, 2014. PMID: 24115073
OPG-Fc but not zoledronic acid discontinuation reverses ONJ in mice. Molon R, Shimamoto H, Bezouglaia O, et al. J Bone Miner Res 30: 1627-1640, 2015. PMID: 25727550
Sclerostin-neutralizing antibody enhances bone regeneration around oral implants. Yu SH, Hao J, Fretwurst T, Liu M, Kostenuik P, Giannobile WV, Jin Q. Tissue Eng Part A. 2018 Nov;24(21-22):1672-1679. PMID: 29921173
Sclerostin and DKK1 inhibition preserves and augments alveolar bone volume and architecture in rats with alveolar bone loss. Liu M, Kurimoto P, Zhang J, Niu QT, Stolina M, Dechow PC, Feng JQ, Hesterman J, Silva MD, Ominsky MS, Richards WG, Ke H, Kostenuik PJ. J Dent Res. 2018 Aug;97(9):1031-1038. PMID: 29617179
Sclerostin neutralizing antibody PLGA microsphere local delivery system for dental implant. Qiming J, Kostenuik P, Liu M, Giannobile W. Int Assoc Dent Res 2018 Annual Meeting
Immobilization of denosumab on titanium affects osteoclastogenesis of human peripheral blood monocytes. Beck F, Hartmann ES, Kohler MI, Schlussel S, Redeker JI, Schmitt B, Fottner A, Unger M, Michael J, Summer B, Kunzelmann K-H, Scharweber D, Kostenuik PJ, Mayer-Wagner S. Int J Mol Sci 2019;20:1002. PMID: 30813507.
Platelet-rich plasma contains high concentrations of DKK1, a potent inhibitor of Wnt signaling that limits bone regeneration and hair growth. Kostenuik P, Mirza F, Collins M. J Orthopedics & Bone Disorders 2023 (in press).
Some of Dr. Kostenuik's publications in the dental field:
Dr. Kostenuik entered the dental research field via collaborations with leading academic experts looking to test novel antiresorptive and bone anabolic agents in dental disease models. Jaw bone loss creates challenges in preserving natural teeth and in placing dental implants, and Paul's own research has investigated the manipulation of osteoclasts and osteoblasts to meet these challenges. Similar approaches also have potential to improve orthodontic procedures through more effective anchorage and mobilization of teeth.
Dr. Kostenuik is an Adjunct Professor at the University of Michigan School of Dentistry, where he also serves as Chair of the Industrial Technologies Advisory Committee and Member of the Operating Committee for DOCTRC, a Dental, Oral, and Craniofacial Tissue Regeneration Consortium. Paul also lectures on mineral homeostasis at the UCLA School of Dentistry, and is a long-time supporter of cleft palate non-profits including SmileTrain.
Dental